Formulary consideration of biosimilars
- At: 2014 FIP Congress in Bangkok (Thailand)
- Type: Presentation
- By: STEVENSON, James (University of Michigan, College of Pharmacy, Ann arbor, United States of America)
Biosimilar medicinal products have been in existence in Europe for years and will soon be available in the United States. Despite the assurance of regulatory bodies to health care professonals that all licensed biosimilar and interchangeable biological products will meet standards for safety and efficacy, concerns have been voiced in the.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.